BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

...clinic; the compound is in Phase I testing to treat solid tumors. Formerly known as Tioma Therapeutics Inc....
BioCentury | Mar 25, 2019
Financial News

Arch Oncology raises $50M series B to develop anti-CD47 mAb

...from existing investors RiverVest Venture Partners, Roche Venture Fund and 3x5 Partners. Arch Oncology, formerly Tioma Therapeutics Inc....
BioCentury | Aug 25, 2016
Targets & Mechanisms

Forty Seven and counting

...the Institute of Stem Cell Biology and Regenerative Medicine at Stanford. Last week's announcement by Tioma Therapeutics Inc....
...PFE), New York, N.Y. Stanford University, Stanford, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Tioma Therapeutics Inc....
...CD19; human bispecific IgG targeting CD47 and mesothelin B cell lymphoma; solid tumors Preclinical Novimmune Tioma Therapeutics Inc....
BioCentury | Aug 22, 2016
Finance

Tioma's broad basket

Tioma Therapeutics Inc. will avoid putting its eggs in one basket and use last week's tranched $86 million series A round to launch a broad clinical program targeting CD47 . President and CEO John Donovan said...
BioCentury | Aug 22, 2016
Financial News

Tioma completes venture financing

Tioma Therapeutics Inc. , Brisbane, Calif. Business: Cancer Date completed: 2016-08-16 Type: Venture financing Raised: $86 million Investors: RiverVest Venture Partners; Novo Ventures; Roche Venture Fund; SR One WIR Staff...
BioCentury | Aug 16, 2016
Top Story

Tioma raises $86M for anti-CD47 antibodies

...Immuno-oncology play Tioma Therapeutics Inc. (Brisbane, Calif.) raised $86 million in a series A round co-led by RiverVest...
Items per page:
1 - 6 of 6
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

...clinic; the compound is in Phase I testing to treat solid tumors. Formerly known as Tioma Therapeutics Inc....
BioCentury | Mar 25, 2019
Financial News

Arch Oncology raises $50M series B to develop anti-CD47 mAb

...from existing investors RiverVest Venture Partners, Roche Venture Fund and 3x5 Partners. Arch Oncology, formerly Tioma Therapeutics Inc....
BioCentury | Aug 25, 2016
Targets & Mechanisms

Forty Seven and counting

...the Institute of Stem Cell Biology and Regenerative Medicine at Stanford. Last week's announcement by Tioma Therapeutics Inc....
...PFE), New York, N.Y. Stanford University, Stanford, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Tioma Therapeutics Inc....
...CD19; human bispecific IgG targeting CD47 and mesothelin B cell lymphoma; solid tumors Preclinical Novimmune Tioma Therapeutics Inc....
BioCentury | Aug 22, 2016
Finance

Tioma's broad basket

Tioma Therapeutics Inc. will avoid putting its eggs in one basket and use last week's tranched $86 million series A round to launch a broad clinical program targeting CD47 . President and CEO John Donovan said...
BioCentury | Aug 22, 2016
Financial News

Tioma completes venture financing

Tioma Therapeutics Inc. , Brisbane, Calif. Business: Cancer Date completed: 2016-08-16 Type: Venture financing Raised: $86 million Investors: RiverVest Venture Partners; Novo Ventures; Roche Venture Fund; SR One WIR Staff...
BioCentury | Aug 16, 2016
Top Story

Tioma raises $86M for anti-CD47 antibodies

...Immuno-oncology play Tioma Therapeutics Inc. (Brisbane, Calif.) raised $86 million in a series A round co-led by RiverVest...
Items per page:
1 - 6 of 6